D.C. Lung Cancer Conference 2024

D.C. Lung Cancer Conference 2024 is organized by MedStar Health and will be held on Oct 19, 2024 at Grand Hyatt Washington, Washington, Dist of Col, United States of America.

Description:
This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past few years, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide an important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on modern bronchoscopy, proton beam radiation, minimally invasive surgery and both neoadjuvant and adjuvant systemic therapy. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over use of emerging biomarkers to guide treatment of advanced NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review.

Objectives:
After completing this activity, the participant will be able to:

• Explain the significance and use of patient centered communications on the patient and family experience.
• Identify the survival benefit of CT screening for lung cancer.
• Discuss the current application of liquid biopsy (or ctDNA analysis).
• Describe the methods used for biomarker testing in lung cancer.
• Explain the approved use of neoadjuvant and perioperative immunotherapy for patients with resectable lung cancer.
• Debate the use of targeted therapy for patients with resected EGFR mutant non-small cell lung cancer.
• Describe current standard care for advanced mesothelioma.
• Describe the best initial therapy for advanced small cell lung cancer (SCLC).
• Describe the benefit of immunotherapy in the treatment of small cell lung cancer.
• Discuss management of immune-mediated toxicities.
• Discuss standard targeted agents in use for patients with ALK-positive non-small cell lung cancer.
• Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
• Name the approved targeted agent for HER2 mutant NSCLC.
• List the currently approved targeted options for patients with MET exon 14 mutant lung cancer.
• Integrate a team-based approach in the care of patients with lung cancer.